These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20721844)

  • 1. [Personalized therapy of gastrointestinal cancers--possibilities and limitations].
    Wichert Gv; Adler G; Seufferlein T
    Dtsch Med Wochenschr; 2010 Aug; 135(34-35):1687-91. PubMed ID: 20721844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 4. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for personalized medicine in GI cancers.
    Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
    Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 8. Palliative chemotherapy in advanced gastrointestinal cancer.
    van Riel JM; van Groeningen CJ
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):391-6. PubMed ID: 10783990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized therapy for metastatic colorectal cancer.
    Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
    J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
    Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
    Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
    Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
    Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A; Graeven U
    Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.
    Paul D; Ostwal V; Bose S; Basu S; Gupta S
    Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):985-90. PubMed ID: 27257869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-Ras mutations are changing practice in advanced colorectal cancer.
    McNeil C
    J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 16. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
    Formica V; Roselli M
    World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers in gastrointestinal cancer: targeted therapy and tailored chemotherapy.
    Lenz HJ
    Onkologie; 2004 Feb; 27(1):12-4. PubMed ID: 15017995
    [No Abstract]   [Full Text] [Related]  

  • 19. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
    Weinberg BA; Hartley ML; Salem ME
    Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.